# Citation

## Latest publication

If you use the Open Targets Platform in your work, please cite our latest publication:

Buniello, A. et al. (2025). [Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery](https://academic.oup.com/nar/article/53/D1/D1467/7917960). *Nucleic Acids Research.*

## Previous publications

We have additional publications about the Open Targets Platform:

* Ochoa, D. et al. (2023). [The next-generation Open Targets Platform: reimagined, redesigned, rebuilt.](https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkac1046/6833237) *Nucleic Acids Research.*
* Ochoa, D. et al. (2021). [Open Targets Platform: supporting systematic drug–target identification and prioritisation](https://doi.org/10.1093/nar/gkaa1027). *Nucleic Acids Research.*
* Carvalho-Silva, D. et al. (2019). [Open Targets Platform: new developments and updates two years on](https://doi.org/10.1093/nar/gky1133). *Nucleic Acids Research*.
* Koscielny, G. et al. (2017). [Open Targets: a platform for therapeutic target identification and validation](https://doi.org/10.1093/nar/gkw1055). *Nucleic Acids Research.*

You can also refer to our publications about Open Targets Genetics and our Locus-to-Gene (L2G) pipeline:

* Ghoussaini, M., et al. (2021) [Open Targets Genetics: systematic identification of trait-associated genes using large-scale genetics and functional genomics](https://doi.org/10.1093/nar/gkaa840). *Nucleic Acids Research*.
* Mountjoy, E., et al. (2021) [An open approach to systematically prioritize causal variants and genes at all published human GWAS trait-associated loci](https://doi.org/10.1038/s41588-021-00945-5). *Nature Genetics.*